Cargando…

Olaparib Versus Nonplatinum Chemotherapy in Patients With Platinum-Sensitive Relapsed Ovarian Cancer and a Germline BRCA1/2 Mutation (SOLO3): A Randomized Phase III Trial

PURPOSE: A phase II study (ClinicalTrials.gov identifier: NCT00628251) showed activity of olaparib capsules versus pegylated liposomal doxorubicin in patients with germline BRCA-mutated platinum-resistant or partially platinum-sensitive relapsed ovarian cancer. We conducted a phase III trial (SOLO3)...

Descripción completa

Detalles Bibliográficos
Autores principales: Penson, Richard T., Valencia, Ricardo Villalobos, Cibula, David, Colombo, Nicoletta, Leath, Charles A., Bidziński, Mariusz, Kim, Jae-Weon, Nam, Joo Hyun, Madry, Radoslaw, Hernández, Carlos, Mora, Paulo A.R., Ryu, Sang Young, Milenkova, Tsveta, Lowe, Elizabeth S., Barker, Laura, Scambia, Giovanni
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Clinical Oncology 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7145583/
https://www.ncbi.nlm.nih.gov/pubmed/32073956
http://dx.doi.org/10.1200/JCO.19.02745